| 000 | 01884 a2200529 4500 | ||
|---|---|---|---|
| 005 | 20250517205815.0 | ||
| 264 | 0 | _c20190806 | |
| 008 | 201908s 0 0 eng d | ||
| 022 | _a1476-5381 | ||
| 024 | 7 |
_a10.1111/bph.14221 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aBrookes, Daniel W | |
| 245 | 0 | 0 |
_aLate therapeutic intervention with a respiratory syncytial virus L-protein polymerase inhibitor, PC786, on respiratory syncytial virus infection in human airway epithelium. _h[electronic resource] |
| 260 |
_bBritish journal of pharmacology _c06 2018 |
||
| 300 |
_a2520-2534 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 |
_aAntiviral Agents _xchemistry |
| 650 | 0 | 4 | _aBenzamides |
| 650 | 0 | 4 | _aBenzazepines |
| 650 | 0 | 4 |
_aDNA-Directed RNA Polymerases _xantagonists & inhibitors |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 |
_aEpithelium _xdrug effects |
| 650 | 0 | 4 | _aHeLa Cells |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMicrobial Sensitivity Tests |
| 650 | 0 | 4 |
_aRespiratory Mucosa _xdrug effects |
| 650 | 0 | 4 |
_aRespiratory Syncytial Virus Infections _xdrug therapy |
| 650 | 0 | 4 |
_aRespiratory Syncytial Virus, Human _xdrug effects |
| 650 | 0 | 4 |
_aSpiro Compounds _xchemistry |
| 650 | 0 | 4 | _aStructure-Activity Relationship |
| 650 | 0 | 4 |
_aVirus Replication _xdrug effects |
| 700 | 1 | _aCoates, Matthew | |
| 700 | 1 | _aAllen, Heather | |
| 700 | 1 | _aDaly, Leah | |
| 700 | 1 | _aConstant, Samuel | |
| 700 | 1 | _aHuang, Song | |
| 700 | 1 | _aHows, Mark | |
| 700 | 1 | _aDavis, Amanda | |
| 700 | 1 | _aCass, Lindsey | |
| 700 | 1 | _aAyrton, John | |
| 700 | 1 | _aKnowles, Ian | |
| 700 | 1 | _aStrong, Pete | |
| 700 | 1 | _aRapeport, Garth | |
| 700 | 1 | _aIto, Kazuhiro | |
| 773 | 0 |
_tBritish journal of pharmacology _gvol. 175 _gno. 12 _gp. 2520-2534 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/bph.14221 _zAvailable from publisher's website |
| 999 |
_c28218234 _d28218234 |
||